US pharma giant Pfizer on Saturday announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...

The Company’s abstract, Evaluation of Teverelix in Healthy Female Volunteers, has been accepted for presentation at American ...

Data from the first in human study on O3R-5671’s potent TNFα inhibition to be presented Dosing of the final cohort in the first in human study has been initiated Studies in ulcerative colitis and ...

FemPulse™, a bioelectronic medical technology company with first application overactive bladder, announced today that an ...

When the iPhone debuted, critics said thumbs couldn’t type on glass. Steve Jobs disagreed. People did learn. But with tech ...

New subgroup analysis shows consistent, clinically meaningful pain reduction observed from Stage 2 through Stage 4 disease, including late-stage ...

A Potential New Standard for First-Line HER2+ Advanced GEA* Combination therapy showed compelling survival and disease control compared to current standard, regardless of PD-L1 status* High GEA burden ...

In an era of technology and uncertainty, scholars highlight how the humanities are vital for understanding global crises, ...

According to Root and the investigative team comprising journalists Eva Hoffmann and Christian Fuchs, the security hygiene on ...

"Show interest in traditional family roles and heritage, using an approachable tone with a mix of warmth and conviction." ...

Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating ...

Q1 2026 Earnings Call Transcript January 8, 2026 Simulations Plus, Inc. misses on earnings expectations. Reported EPS is ...